SCHEMBL16756328

SCHEMBL16756328

Cc1nc2cc(C3CCN(C(=O)O)CC3)ccc2n1Cc1ccccc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.39
▸ PPARG P37231 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAP3K7 O43318 1/20 0.38
▸ TAB1 Q15750 1/20 0.38
▸ MGLL Q99685 1/20 0.37
▸ BCHE P06276 2/20 0.37
▸ ACHE P22303 2/20 0.37
▸ HRH3 Q9Y5N1 3/20 0.37
▸ MAPT P10636 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16756319 0.85 TLR9 (0.41) MEN1KMT2AMAP3K7TAB1HRH3
SCHEMBL16756330 0.84 P2RX3 (0.38) MEN1KMT2AMAP3K7TAB1HRH3
SCHEMBL16756565 0.83 MEN1 (0.39) MEN1KMT2AMAP3K7TAB1HRH3
SCHEMBL16756314 0.79 ALDH1A1 (0.37) RAB9AMEN1KMT2AKDM4EALDH1A1
SCHEMBL16756406 0.79 PPARD (0.39) MEN1KMT2AMAP3K7TAB1
SCHEMBL16756365 0.78 TLR7 (0.43) RAB9ANPC1GALR3NR2F2
SCHEMBL28860467 0.75 GALR3 (0.62) RAB9AMEN1KMT2AKDM4EALDH1A1
SCHEMBL16756302 0.74 PPARD (0.40) MGLLKDM4E
SCHEMBL16756466 0.74 GALR3 (0.43) RAB9APPARGMEN1KMT2AMAPT
SCHEMBL16756251 0.74 WNT3A (0.41) MEN1KMT2AMAP3K7TAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858983-B1 TNF-ALPHA MODULATING BENZIMIDAZOLES UCB BIOPHARMA SPRL (BE) 2018-04-18 — — EP disclosed
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 — — US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA RAB9A 1951/4885PPARG 893/4885MEN1 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback